Clinical analysis of liver damage of malignant lymphoma patients with positive HBV surface antigen(HBsAg)after rituximab and chemotherapy
10.3760/cma.j.issn.1009-9921.2008.06.007
- VernacularTitle:乙肝表面抗原阳性淋巴瘤患者19例利妥昔单抗联合化疗肝功能损害分析
- Author:
Yan XIE
;
Jun ZHU
;
Wen ZHENG
;
Yuntao ZHANG
;
Xiaopei WANG
;
Yuqin SONG
;
Meifeng TU
- Publication Type:Journal Article
- Keywords:
Lymphoma,non-Hodgkin;
Hepatitis B surface antigens;
Antineoplastic combinedchemotherapy protocols
- From:
Journal of Leukemia & Lymphoma
2008;17(6):421-423
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the prevalence of liver damage in B-cell lymphoma patients with positive HBV surface antigen(HBsAg)after rituximab and chemotherapy.Methods Records of 19 B-cell lymphoma patients with positive HBV surface antigen(HBsAg)after rituximab and chemotherapy from June,2001 to Aug,2007 in Beijing Cancer Hospital were reviewed to analyze the prevalence of liver damage.At the same time,the relationship between the level of HBV-DNA and the damage of liver was analysed.Results According to WHO criteria of liver toxicity,of the 19 patients,12(63.2%)suffered liver damage,4(21.1%)patients in grade Ⅰ,6(31.2%)patients in grade Ⅱ and 2(10.5%)patients in grade Ⅲ.None of the patients in this study experienced grade Ⅳ liver toxicity.Of the 6 patients with HBV-DNA＞104 copy/ml before therapy,5(83.3%)suffered liver damage.Of the 5 patients with HBV-DNA＜104 copy/ml before therapy,3(60%)suffered liver damage.Conclusion The prevalence of liver damage is higher in B-cell lymphoma patients with positive HBsAg after rituximab and chemotherapy.These patients should be closely monitored for liver function when they received rituximab therapy and should reveive anti-HBV therapy.
